Where does Christoph Lengauer work?

Christoph Lengauer is Founder of Blueprint Medicines and Partner at Third Rock Ventures and Board director at Hookipa Pharma.

What companies did Christoph Lengauer found?

Christoph Lengauer founded Blueprint Medicines.

What boards does Christoph Lengauer sit on?

Christoph Lengauer holds tracked board seats at Hookipa Pharma.

Where did Christoph Lengauer go to school?

Christoph Lengauer studied at The Johns Hopkins University - Carey Business School (MBA, Medical Services Management); The Johns Hopkins University (Postdoc, Molecular Biology); Research Institute of Molecular Pathology (Postdoc, Molecular Biology).

Christoph Lengauer

InvestorFounder

Partner at Third Rock Ventures · CSO at Curie.Bio · Board director at Hookipa Pharma · Executive Officer, Director at Celsius Therapeutics · Founder at Blueprint Medicines

Boston, Massachusetts, United States

FoundedBlueprint Medicines

Find your path to Christoph

765 people in our graph share verified history with Christoph — schools, employers, funds. One of them is your warm intro.

Dan LynchunlockedChristoph: together at Blueprint Medicines (2012–2021)

Christoph: together at The Johns Hopkins University

×5Christoph: together at Third Rock Ventures

×2Christoph: together at Cancerresearchuk

About

Christoph Lengauer is the co-founder and Chief Scientific Officer of Curie.Bio, where he supports founders launching therapeutics companies. His work combines drug development expertise, services, and seed capital to help move companies from initial concept through Series A financing.

Contact· published on Christoph's own website

c•••@curie.bioreveal

Board director at Hookipa Pharma

Intro paths

→

In turn, Christoph can intro founders to Hookipa Pharma's investors below.

Hookipa Pharma's investors · 2

Sofinnova PartnersParis · $540K – $27M checks · since 2019 Third Rock VenturesBoston · $100K – $5M checks · since 2019

Executive Officer, Director at Celsius Therapeutics

Intro paths

→

In turn, Christoph can intro founders to Celsius Therapeutics's investors below.

Celsius Therapeutics's investors · 6

AlexandriaPasadena Casdin CapitalNew York Catalio Capital Management, LPNew York Fast Track InitiativeTokyo · $1.2M – $184M checks GV (Google Ventures)Mountain View · $250K – $50M checks Third Rock VenturesBoston · $100K – $5M checks

Founder at Blueprint Medicines

Intro paths

→

In turn, Christoph can intro founders to Blueprint Medicines's investors below.

Blueprint Medicines's investors · 4

F-Prime CapitalCambridge · $3M – $10M checks Foresite CapitalWest Hollywood Nextech InvestZurich · $648K – $3.2M checks RA CapitalBoston

Co-founders at Blueprint Medicines

Nick LydonDirector

Experience

Curie.BioCSO & co-foundercurrent2022 — presentanywhere you want it to be
Cancer Research UK (CRUK)Board Member of Cancer Research Horizons and Therapeutic Innovationcurrent2023 — presentLondon Area, United Kingdom
Johns Hopkins UniversityAdjunct Associate Professorcurrent2005 — presentBaltimore, MD
Johns Hopkins UniversityPrincipal Investigator1994 — 2005Baltimore, MD
Thrive, An Exact Sciences CompanyConsultant, R&D strategy2021 — 2022Cambridge, MA
Thrive, An Exact Sciences CompanyChief Innovation Officer & co-founder2019 — 2021Cambridge, MA and Baltimore, MD
Advise Connect Inspire (ACI)CEO & founder2017 — 2022Greater Boston Area
Third Rock VenturesPartner2018 — 2022Boston, MA
Third Rock VenturesVenture Partner2016 — 2018Boston, MA
Blueprint MedicinesExecutive Vice President2016 — 2021Cambridge, MA
Blueprint MedicinesCSO & Chief Drug Hunter2012 — 2016Cambridge, MA
MOMA TherapeuticsCSO & co-founder2020 — 2021Cambridge, MA
Celsius TherapeuticsCSO, president & co-founder2018 — 2020Cambridge, MA
Creative Destruction LabAssociate2018 — 2019Toronto, Canada Area
German Accelerator Life SciencesCEO2015 — 2019Cambridge, MA
SanofiGlobal Head of Oncology Drug Discovery and Preclinical Development2008 — 2012Paris Area, France & Cambridge, MA
NovartisUnit Head - Oncology Drug Discovery2005 — 2008Cambridge, MA

Skills & more

Entrepreneurship2Drug Discovery

From Christoph's professional profile.

Deals · 1

Hookipa PharmaBoard seat

via Third Rock Ventures · filed Feb 2019

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Third Rock Ventures

Abbie Celniker

Investor at Third Rock Ventures

Adam Tebbe

Investor at Third Rock Ventures

Alan Ezekowitz

Investor at Third Rock Ventures

Alexis Borisy

General Partner at Third Rock Ventures

Alison Connors

Investor at Third Rock Ventures

Amanda Chan

Investor at Third Rock Ventures

Andrea van Elsas

Investor at Third Rock Ventures

Angelo Severino

Investor at Third Rock Ventures

Network5

Abbie Celniker

Investor at Third Rock Ventures

Alan Ezekowitz

Investor at Third Rock Ventures

Andrea van Elsas

Investor at Third Rock Ventures

Andrew Warren

Senior Associate at Third Rock Ventures

Barbara Weber

Venture Partner at Third Rock Ventures

Investors connected to Christoph in public investor directories — a warm-intro map.

Frequently asked questions

Who is Christoph Lengauer?: Christoph Lengauer is the co-founder and Chief Scientific Officer of Curie.Bio, where he supports founders launching therapeutics companies. His work combines drug development expertise, services, and seed capital to help move companies from initial concept through Series A financing.
Where does Christoph Lengauer work?: Christoph Lengauer is Founder of Blueprint Medicines and Partner at Third Rock Ventures and Board director at Hookipa Pharma.
What companies did Christoph Lengauer found?: Christoph Lengauer founded Blueprint Medicines.
What boards does Christoph Lengauer sit on?: Christoph Lengauer holds tracked board seats at Hookipa Pharma.
Where did Christoph Lengauer go to school?: Christoph Lengauer studied at The Johns Hopkins University - Carey Business School (MBA, Medical Services Management); The Johns Hopkins University (Postdoc, Molecular Biology); Research Institute of Molecular Pathology (Postdoc, Molecular Biology).